Home >> Research Area >>TGF-β/Smad Signaling>> Nilotinib(AMN-107)

Nilotinib(AMN-107)

Bcr-Abl kinase inhibitor,selective CAS# 641571-10-0

Nilotinib(AMN-107)

Catalog No. BCC3643----Order now to get a substantial discount!

Product Name & Size Price Stock
Nilotinib(AMN-107): 5mg $6 In Stock
Nilotinib(AMN-107): 10mg Please Inquire In Stock
Nilotinib(AMN-107): 20mg Please Inquire Please Inquire
Nilotinib(AMN-107): 50mg Please Inquire Please Inquire
Nilotinib(AMN-107): 100mg Please Inquire Please Inquire
Nilotinib(AMN-107): 200mg Please Inquire Please Inquire
Nilotinib(AMN-107): 500mg Please Inquire Please Inquire
Nilotinib(AMN-107): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Nilotinib(AMN-107)

Number of papers citing our products

Chemical structure

Nilotinib(AMN-107)

3D structure

Chemical Properties of Nilotinib(AMN-107)

Cas No. 641571-10-0 SDF Download SDF
PubChem ID 644241 Appearance Powder
Formula C28H22F3N7O M.Wt 529.53
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Tasigna; AMN107
Solubility DMSO : 6 mg/mL (11.33 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
SMILES CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5
Standard InChIKey HHZIURLSWUIHRB-UHFFFAOYSA-N
Standard InChI InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Nilotinib(AMN-107)

DescriptionNilotinib (AMN-107) is an inhibitor of Bcr-Abl with IC50 less than 30 nM.
TargetsBcr-Abl    
IC5030 nM     

Protocol

Cell experiment: [1]

Cell lines

CD34+ cells from individual patients with CML

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

5 μM, 16 hours

Applications

After 16 hours in culture with nilotinib, long enough for inhibition of CrkL phosphorylation but not for induction of apoptosis, the total CD34+ cell samples studied exhibited only partial and variable inhibition (range, 49% to 0% inhibition) of CrkL phosphorylation.

Animal experiment: [2]

Animal models

C57Bl/6J mice injected with 8093 lymphoma cells

Dosage form

Oral administration, 75 mg/kg, daily

Application

Vehicle treated mice became moribund within 3 weeks of the transplantation. They showed clear symptoms of ALL. Nilotinib-treated mice lived statistically significantly longer as compared with the vehicle-treated mice. This result clearly indicated that nilotinib was very effective in inhibiting the proliferation of the leukemic cells in vivo.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Jørgensen H G, Allan E K, Jordanides N E, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 2007, 109(9): 4016-4019.

[2] Kaur P, Feldhahn N, Zhang B, et al. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer, 2007, 6(10): 67-77.

Nilotinib(AMN-107) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Nilotinib(AMN-107) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Nilotinib(AMN-107)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.8885 mL 9.4423 mL 18.8847 mL 37.7693 mL 47.2117 mL
5 mM 0.3777 mL 1.8885 mL 3.7769 mL 7.5539 mL 9.4423 mL
10 mM 0.1888 mL 0.9442 mL 1.8885 mL 3.7769 mL 4.7212 mL
50 mM 0.0378 mL 0.1888 mL 0.3777 mL 0.7554 mL 0.9442 mL
100 mM 0.0189 mL 0.0944 mL 0.1888 mL 0.3777 mL 0.4721 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Nilotinib(AMN-107)

Nilotinib is a selective, oral inhibitor of tyrosine kinase with IC50 values of 20, 42, 31, 38, 29 and 41 nM for the autophosphorylation of native BCR-ABL (WT p210) and mutant BCR-ABL (E281K, E292K, F317L, M351T and F486S), respectively [1].

Nilotinib was designed based on the structure of imatinib and showed the superiority over imatinib in newly diagnosed or imatinib-resistant chronic myelogenous leukemia (CML). It was more potent than imatinib to wild-type BCR-ABL in a wide range of CML-derived and transfected cell lines. Nilotinib was also efficacious in gastrointestinal stromal tumors. Nilotinib showed inhibition activities in KIT mutant cells, including KITV560del, KITK642E and KITV560G (IC50 value of 108 nM). It also was effect to double mutations of KIT, such as KITV560del/V654A, KITV559D/D820Y, KITV560del/V654A (IC50: 192 nM) and KITV559D/D820Y (IC50: 297 nM). Besides that, Nilotinib exerted selective inhibition of PDGFRα and PDGFRβ. It suppressed cell proliferation with IC50 value of 0.54 nM in EOL-1 cells with constitutive activation of FIP1L1-PDGFRα [1, 2].

References:
[1] Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. British Journal of Cancer, 2006, 94(12): 1765-1769.
[2] Blay J Y, Von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor//Seminars in oncology. WB Saunders, 2011, 38: S3-S9.

Featured Products
New Products
 

References on Nilotinib(AMN-107)

Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.[Pubmed:19188713]

Chemotherapy. 2009;55(2):132-6.

Nilotinib is a novel tyrosine kinase inhibitor targeting KIT (CD117), PDGFR and BCR-ABL and inhibiting the proliferation of both imatinib-sensitive and imatinib-resistant cells in vitro. Nilotinib, alone or in combination with imatinib, has promising activity in imatinib-resistant patients with advanced gastrointestinal stromal tumors (GISTs), including those who progressed on sunitinib and other tyrosine kinase inhibitors. We describe the beneficial effect of nilotinib 400 mg b.i.d. orally in a 53-year-old patient with metastatic GISTs who had radiologically confirmed disease progression on both imatinib (800 mg/day) and sunitinib (50 mg/day). A positron emission tomography-computerized tomography evaluation showed marked decreases in (18)F-fluorodeoxyglucose uptake in the liver and mesentery region after 3 months of therapy with nilotinib. Nilotinib is an option for patients with advanced GISTs progressing on both imatinib and sunitinib.

Description

Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.

Keywords:

Nilotinib(AMN-107),641571-10-0,Tasigna; AMN107,Natural Products, buy Nilotinib(AMN-107) , Nilotinib(AMN-107) supplier , purchase Nilotinib(AMN-107) , Nilotinib(AMN-107) cost , Nilotinib(AMN-107) manufacturer , order Nilotinib(AMN-107) , high purity Nilotinib(AMN-107)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: